Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

A new meta-analysis examines the effects of dual antiplatelet therapy after thrombolysis in minor stroke patients. Findings ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effecti ...

Clinuvel Pharmaceuticals (ASX:CUV) has reported encouraging preliminary results from its second study of afamelanotide in ...

Hyderabad: Apollo Hospitals organised the STAT-2025 Conference on Stroke Thrombolysis and Thrombectomy with leading ...

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

It estimated that 20% of stroke patients could benefit from thrombolysis, a drug that breaks down a clot and returns blood supply to the brain, which should be administered within four and a half ...

Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase), which is also marketed by Genentech. Notably, off-label tenecteplase had already become ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.